

# To improve the lives of patients by creating & developing innovative antibody products



## Approved Partnered Products Solid Financial Base

DARZALEX® (daratumumab) / DARZALEX FASPRO™ (daratumumab & hyaluronidase-fihj)<sup>1</sup>, Kesimpta® (ofatumumab)<sup>2</sup>, TEPEZZA® (teprotumumab)<sup>3</sup> Azerra® (ofatumumab)<sup>4</sup>



## Our Own Clinical Pipeline Potential first-in-class / Best-in-class

Tisotumab vedotin<sup>5</sup>, enapotamab vedotin, HexaBody®-DR5/DR5, epcoritamab<sup>6</sup>, DuoBody-PD-L1x4-1BB (GEN1046)<sup>7</sup>, DuoBody-CD40x4-1BB (GEN1042)<sup>7</sup> DuoHexaBody®-CD37 (GEN309)<sup>6</sup> & DuoBody®-CD3x5T4 (GEN1044)<sup>6</sup>



## Partner-owned Programs in the Clinic Programs Built on Genmab's Innovation

10 in clinical development with partners with royalty streams for Genmab should they come to market. Includes 6 DuoBody products with Janssen



## Technologies & Preclinical R&D Engine: Powerhouse of Innovation

DuoBody tech., HexaBody tech., DuoHexaBody tech., HexElect® tech. & Rich preclinical pipeline incl. HexaBody-CD38 (GEN3014)<sup>8</sup>



## Our Three-pronged Strategy

- Focus on core competence
- Turn science into medicine
- Build a profitable & successful biotech



## Our Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies



Proprietary technologies allow us to build a world-class pipeline

Match in-house expertise with strategic partnerships



Deep insight into antibody biology & disease targets

Strong pipeline of first-in-class / best-in-class products

### 2020 Guidance

Income Statement	DKKM	USDM <sup>9</sup>
Revenue	9,250 – 9,850	1,423 – 1,515
Operating expenses	(3,850) – (3,950)	(592) – (608)
Operating income	5,350 – 5,950	823 - 915

<sup>9</sup>USD 1.00 = DKK 6.50

DKK  
**96B**  
~USD 14B<sup>10</sup>  
2019 year-end market cap


<sup>10</sup>USD 1.00 = DKK 6.6759

DKK  
**2,728M**  
~USD 408M<sup>10</sup>  
2019 operating expenses  
87% invested in R&D

DKK  
**5,366M**  
~USD 803M<sup>10</sup>  
2019 revenue  
77% increase vs 2018

DKK  
**10,971M**  
~USD 1,643M<sup>10</sup>  
2019 year end cash position

### Revenue MDDK (~MUSD<sup>10</sup>)



# Innovation Powerhouse

## Genmab Proprietary<sup>11</sup> Products

Product	Target	Rights	Indications	Most Advanced Dev. Phase					
				Pre-clin.	I	I/II	II	III	Appr.
Tisotumab vedotin	TF	50:50 Genmab Seattle Genetics	Cervical cancer Ovarian cancer Solid tumors						
Enapotamab vedotin	AXL	Genmab	Solid tumors						
Epcoritamab	CD3, CD20	50:50 Genmab AbbVie	Hem. malig.						
DuoBody-PD-L1x4-1BB	PD-L1, 4-1BB	50:50 Genmab BioNTech	Solid tumors						
DuoBody-CD40x4-1BB	CD40, 4-1BB	50:50 Genmab BioNTech	Solid tumors						
HexaBody-DR5/DR5	DR5	Genmab	Solid tumors						
DuoHexaBody-CD37	CD37	50:50 Genmab AbbVie	Hem. malig.						
DuoBody-CD3x5T4	5T4	50:50 Genmab AbbVie	Solid tumors						

IND/CTAs in 2020: HexaBody-CD38<sup>12</sup>

## Products Created by Genmab<sup>13</sup>

Daratumumab	CD38	Janssen <sup>14</sup>	MM AL Amyloidosis Non-MM blood cancers						
Ofatumumab	CD20	Novartis <sup>14,15</sup>	RMS						
Teprotumumab	IGF-1R	Horizon <sup>14</sup>	TED						

## Partner-owned products incorporating Genmab's Innovation<sup>16</sup>

Camidanlumab tesirine	CD25	ADC Therapeutics	R/R Hodgkin lymphoma Solid tumors						
Mim8	FIX(a), FX	Novo Nordisk	Hemophilia A						
Humax-IL8	IL8	BMS	Advanced cancers						
Amivantamab (JNJ-61186372)	EGFR, cMet	Janssen	NSCLC						
JNJ-63709178	CD123, CD3	Janssen	AML						
Teclistamab (JNJ-64007957)	BCMA, CD3	Janssen	R/R MM						
Talquetamab (JNJ-64407564)	GPRC5D, CD3	Janssen	R/R MM						
JNJ-67571244	CD33, CD3	Janssen	R/R AML or MDS						
JNJ-63898081	PSMA, CD3	Janssen	Solid tumors						
Lu AF82422	α synuclein	Lundbeck	Parkinson's						

~20 active pre-clinical programs Partnered & proprietary programs: HuMab, DuoBody, DuoHexaBody and HexaBody

# Products & Technologies

## Tisotumab vedotin

- ADC in development to treat solid tumors
- Very favorable data, Ph 2 cervical cancer
- Ph 2 studies in ovarian & other solid tumors
- 50:50 agreement w/ Seattle Genetics

## Enapotamab vedotin

- ADC in development to treat solid tumors
- Ph 1/2 trial for multiple solid tumors

## HexaBody-DR5/DR5 (GEN1029)

- Proprietary antibody therapeutic
- Phase 1/2 trial in solid tumors

## Epcoritamab (DuoBody-CD3xCD20)

- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in B-cell malignancies
- 50:50 collaboration w/ AbbVie

## DuoBody-PD-L1x4-1BB (GEN1046)

- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in solid tumors
- 50:50 agreement w/ BioNTech

## DuoBody-CD40x4-1BB (GEN1042)

- Bispecific antibody created w/ DuoBody tech
- Phase 1/2 trial in solid tumors
- 50:50 agreement w/ BioNTech

## DuoHexaBody-CD37 (GEN3009)

- Based on combo DuoBody & HexaBody
- FiH trial commenced
- 50:50 collaboration w/ AbbVie

## DuoBody-CD3x5T4 (GEN1044)

- Bispecific antibody created w/ DuoBody tech
- FiH trial commenced
- 50:50 collaboration w/ AbbVie

## Kesimpta (ofatumumab)

- SubQ formulation approved in US for RMS<sup>14</sup>
- In development by Novartis

**Founded:** 1999

**Exchanges:** CSE / Nasdaq

**Symbol:** GMAB

**Shares outstanding:** 65,346,580

**Market Cap as of Aug 20, 2020:**

DKK 153B (~USD 24,528M)

## DARZALEX (daratumumab) / DARZALEX FASPRO (daratumumab & hyaluronidase-fihj)

- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications<sup>14</sup>
- First & only SC CD38 antibody approved
- In development by Janssen
- 2019 net sales by Janssen: \$2,998M, DKK 3,132M royalties to Genmab

## TEPEZZA (teprotumumab)

- Dev. & manufactured by Horizon Therapeutics
- Approved in US for thyroid eye disease<sup>14</sup>
- Created under collaboration with Roche
- Under terms of agreement with Roche, Genmab to receive mid-single digit royalties on sales

## DuoBody Platform

- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

## HexaBody Platform

- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

## DuoHexaBody Platform

- Antibody technology that combines DuoBody & HexaBody platforms
- Creates bispecific antibodies with target-mediated enhanced potency

## HexElect Platform

- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting with enhanced selectivity & potency

## Executive Management:

Jan G. J. van de Winkel, Ph.D. President & CEO

Anthony Pagano, EVP & CFO

Judith Klimovsky M.D., EVP & CDO

Anthony Mancini, EVP & COO

<sup>11</sup>Certain product candidates in development with partners, as noted

<sup>12</sup>Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc.

<sup>13</sup>Out-licensed products marketed by partner

<sup>14</sup>See local country prescribing information for precise indications

<sup>15</sup>Also approved as Arzerra for certain CLL indications, not in active clinical development

<sup>16</sup>Products under development by a third-party incorporating Genmab's technology and innovation.